

February 08, 2016

Cardiovascular Biotherapeutics Inc. Announces It Has Moved Its Headquarters To Texas

Dallas, TX, February 8, 2016 - CardioVascular BioTherapeutics, Inc. ("CVBT" or the "Company"). CVBT is pleased to announce that its Corporate Headquarters and Administrative Offices have moved to Dallas, Texas. The new address for CVBT is 9870 Plano Rd., Dallas, TX 75238. CVBT's phone number 702-839-7200 will be forwarded to 972-681- 9368. You can call either phone number to get through to CVBT.

In addition to being the home of the largest medical center in the world, Texas Medical Center, Texas has over 3,600 companies involved in the biotech industry, and a very active biotech VC community, which, according to the National Institute of Health, is involved in supporting the second largest number of ongoing clinical trials among the 50 States.

CVBT's President, Mickael A. Flaa, stated: "This is an important and positive move for CVBT. The Company has not been located in a biotech hub since it left California in 2005. Being involved in this vibrant and growing biotech community creates great opportunities for CVBT."

About Texas Medicine and Biotech

3,600 Biotech Firms: Texas is home to more than 3,600 firms engaged in biotechnology R&D and manufacturing.

World's Largest: Texas Medical Center (TMC) in Houston is considered the largest concentration of medical professionals and experts in the world, and the 8th largest business district in the world. It conducts \$3.4 billion in research annually; it even has its own orchestra. The TMC is a significant source of innovation and growth for the industry. With more than 49,000 students and 106,000 employees housed on over 1,300 acres, the TMC houses 54 member institutions, including 26 private nonprofit health-related institutions and 14 hospitals.

\$1.3 Billion: From 2008 to 2013, venture capitalists invested \$1.3 billion in 161 biotech and medical device deals.

16,900 Studies: In April 2014, NIH ranked Texas second in the nation for the number of ongoing clinical trials, with more than 16,900 studies underway. Many of the world's leading clinical trial and contract research firms have operations across Texas, including PPD, Covance, Quintiles, INC Research, inVentiv Health Clinical and Radiant Research. The state has raised \$145 million in biomedicine and pharmaceutical projects through the Texas Emerging Technology Fund (TETF).

Source <https://texaswideopenforbusiness.com/industries/biotechnology-life-sciences>

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates for diseases characterized by inadequate blood flow to tissue or organs. The company is the sponsor of a currently paused Phase II trial to treat severe coronary heart disease (CVBT-141H), and has received FDA authorization for a Phase I trial to treat peripheral arterial disease (CVBT-141C). A Late-Stage trial to treat chronic diabetic foot ulcers (CVBT-141B) is planned pending FDA approval.

Forward Looking Statements

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. Additionally, until CVBT is cash flow positive from operations, the Company is dependent upon raising capital to fund its operations and meet its obligations as they come due. There can be no assurance that CVBT will be able to raise the necessary capital when needed.

SOURCE: CardioVascular BioTherapeutics, Inc.